Skip to main content
. 2017 Mar 17;356:j1065. doi: 10.1136/bmj.j1065

Table 3.

Subgroup analysis with primary outcome in risk group by continued or discontinued anticoagulants in events (%) per 100 patient years (95% confidence intervals)

Groups Low risk women* who discontinued oral anticoagulants (n=591)
Age <50 (n=429): 2.0 (0.8 to 3.9)
 Oestrogen (n=291) 1.4 (0.4 to 3.7)
 No oestrogen (n=138) 3.1 (0.8 to 7.9)
Age ≥50 (n=162): 5.7 (2.6 to 10.9)
 Oestrogen (n=24) 0
 No oestrogen (n=138) 6.8 (3.1 to 12.8)
Type of index VTE:
 Isolated DVT (n=177) 3.0 (1.0 to 7.0)
 Isolated PE (n=323) 3.9 (2.0 to 6.8)
 DVT and PE (n=91) 0
Country or region:
 North America (n=334) 3.7 (1.9 to 6.6)
 Europe (n=207) 2.5 (0.1 to 5.9)
 India (n=47) 0
 Australia (n=3) 0
Anticoagulant at baseline or enrolment visit:
 Vitamin K antagonist (n=459) 2.9 (1.6 to 5.0)
 All non-vitamin K antagonists (n=132) 3.2 (0.9 to 8.3)
Known “weak” thrombophilia:
 Factor V Leiden (n=59) 3.5 (0.4 to 12.6)
 Prothrombin gene variant (n=26) 3.9 (0.1 to 21.6)

VTE=venous thromboembolism; CVT=deep vein thrombosis; PE=pulmonary embolism.

*HERDOO2 criteria: hyperpigmentation, oedema, or redness in either leg at 5-12 months at baseline or enrolment visit, VIDAS D-dimer ≥250 μg/L during anticoagulant treatment, obesity with body mass index ≥30, or older age, ≥65 years. Low risk=0 or 1 of the criteria present.